BioLargo (BLGO) Q1 2021 Earnings Webcast and Conference Call Wednesday, May 19, 2021 - 4:30 PM Eastern Time

May 12, 2021 8:30 AM

WESTMINSTER, CA / ACCESSWIRE / May 12, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable clean- technologies and full-service environmental engineering company, will host an investor webcast and conference call on Wednesday May 19, 2021, at 1:30 pm PT / 4:30 pm ET, open to the public. The webcast and conference call will be held to review the company's financial results, discuss recent company developments, and conduct a...

Read more

Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted

May 12, 2021 7:05 AM

New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces further expansion of its intellectual property portfolio with its first-ever patent...

Read more

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results

May 12, 2021 7:00 AM

Continued Execution on Xcart™ Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind-Enabling Studies in the United States Licensing Partners Leveraging PolyXen® Platform Technology Continue To Make Clinical, Regulatory and Commercial Advancement FRAMINGHAM, MA / ACCESSWIRE / May 12, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or...

Read more

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

May 11, 2021 4:01 PM

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment for high-intermediate and...

Read more

Havn Life Develops New Method for Rapid Psilocybin Testing

May 11, 2021 8:00 AM

Havn Life has completed its analytical work under its Health Canada Section 56 exemption VANCOUVER, BC / ACCESSWIRE / May 11, 2021 / Havn Life Sciences Inc. (CSE:HAVN) (OTC PINK:HAVLF) (FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it has completed the analytical work...

Read more

Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million

May 11, 2021 8:00 AM

RICHMOND HILL, ON / ACCESSWIRE / May 11, 2021 / Helix BioPharma Corp.(TSX:HBP)("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive convertible security funding agreement (the "Agreement") with Lind Global Macro Fund, LP, a New York based institutional investment fund managed...

Read more

AngioSoma, Inc. Is Pleased To Welcome Darryl Morris As A Strategic Economic Advisor

May 11, 2021 7:19 AM

Morris' economic, strategic, and market intellingence experience will play a key role in the growth of AngioSoma. RICHLAND, WA / ACCESSWIRE / May 11, 2021 / AngioSoma, Inc. (OTC PINK:SOAN) has added Darryl Morris as a Strategic Economic Advisor. Morris has over three decades of economic, strategic, and market intelligence experience working with companies, such as Abbott Laboratories. Headquartered in Richland, Washington,...

Read more

Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

May 11, 2021 6:30 AM

First ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 11, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today the acceleration...

Read more

Applied UV to Host Q1 2021 Conference Call on May 17th

May 10, 2021 11:45 AM

MOUNT VERNON, NY / ACCESSWIRE / May 10, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will host an investor conference call...

Read more

Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit

May 10, 2021 8:30 AM

Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive...

Read more

Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021

May 10, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2021 investor call on Monday, May 17, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update. To...

Read more

Liviana Artisanal CBD Olive Oils Have Arrived

May 7, 2021 9:05 AM

CAPE TOWN, SA / ACCESSWIRE / May 7, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update: The Liviana CBD Infused Extra Virgin Olive Oils first batch is ready to hit the shelves. The premium product range consists of: Estate Select Extra Virgin...

Read more

Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer

May 7, 2021 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon cancer. The program entails identifying small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially critical immune cell...

Read more

Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial

May 6, 2021 7:30 AM

First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 6, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development today announced the start of the REBORN1© clinical trial. This...

Read more

Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1

May 6, 2021 7:00 AM

Up to 2,178% more CBD delivered into bloodstream* Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study...

Read more

American CryoStem Executes LOI with Advanced Regenerative Associates to Conduct Wound Healing Clinical Study

May 6, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / May 6, 2021 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced today, that it has signed a Letter of Intent (LOI) with Advanced Regenerative Associates, LLC ("ARA") of Tinton Falls, NJ for the development of a cell-based wound covering treatment for non-healing wounds, skin ulcers,...

Read more

Molecular Partners' COVID-19 Antiviral Candidate, Ensovibep, Maintains Potent Neutralization Against Emerging Viral Variants In Vitro

May 6, 2021 1:00 AM

In Vitro Studies Show Ensovibep (MP0420) Maintains Full Potency Against the Known Mutations of SARS-CoV-2, Including Those Present in Variants First Identified in Brazil, California, India, and New York, in Addition to the Previously Reported Varia Ongoing Phase 2 Pilot Study of Ensovibep in Ambulatory Patients Now Expanding Into Second Cohort Two Global Phase 2 and 3 Clinical Studies of Ensovibep on Track for...

Read more

Wuhan General Group Secures Lab for Hemp and Mycelium Eco-Friendly Research & Development

May 5, 2021 9:15 AM

CAPE TOWN, SA / ACCESSWIRE / May 5, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update: The hemp and mycelium eco-friendly R&D division of M2Bio Sciences, has secured a laboratory facility near its Woodstock office in Cape Town, South Africa....

Read more

Jubilant Radiopharma and Cylcomedica Europe Announce Their Partnership for the Distribution of RUBY-FILL(R) During the International Conference on Nuclear Cardiology

May 5, 2021 8:00 AM

YARDLEY, PA / ACCESSWIRE / May 5, 2021 / Jubilant Radiopharma, a business division of Jubilant Pharma Limited, and Cyclomedica Europe Ltd, a wholly owned subsidiary of Cyclopharm Limited (ASX:CYC), will announce their partnership at the International Conference on Nuclear Cardiology and Cardiac CT (ICNC), taking place on May 9-11, 2021. Under the terms of the agreement, Cyclomedica was appointed the exclusive distributor of Jubilant...

Read more

RepliCel Announces Record Year in Patents Granted

May 5, 2021 6:00 AM

Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation regenerative medicine technologies in aesthetics and orthopedics, is pleased to announce the granting...

Read more